laprituximab emtansine (IMGN289) / AbbVie - LARVOL DELTA

ImmunoGen, Inc. announces 2015 outlook for product pipeline (Immunogen Press Release) - "Expected 2015 events [for IMGN529] include selection of recommended P2 dose in 1H 2015, start of initial efficacy testing, including as a treatment for relapsed/refractory DLBCL and for CLL in 2Q/3Q 2015 and presentation of updated clinical data in 2H 2015....2015 expectations [for IMGN289 include initiation of a] dose-finding P1 clinical testing for the treatment of EGFR-positive solid tumors....[Anticipated] Submission of Investigational New Drug Application (IND) [for IMGN779] 2H 2015."

Anticipated clinical data • Anticipated IND • Anticipated new P1 trial • Pipeline update • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

IMGN289, an EGFR-targeting antibody-drug conjugate, is effective against tumor cells that are resistant to EGFR tyrosine kinase inhibitors (AACR 2014) - Presentation time: Tuesday, Apr 08, 2014, 1:00 PM - 5:00 PM; Abstract #4513; “The HCC827-ER-E4 cell line expressed mesenchymal markers and acquired a mesenchymal phenotype. It expressed lower levels of EGFR, HER3 and MET compared to the parental cell line and showed no loss of PTEN." 

Preclinical • Non Small Cell Lung Cancer • Oncology

Development of a novel antibody-maytansinoid conjugate, IMGN289, for the treatment of EGFR-expressing solid tumors (AACR 2013) - Abstract#: 5463; Presentation Time: Wednesday, Apr 10, 2013, 8:00 AM -12:00 PM; “IMGN289 combines EGFR inhibition mediated by its J2898A Ab component with the potent cytotoxicity provided by its DM1 payload, and is highly active against EGFR-positive tumors regardless of their dependency on the EGFR pathway.”

Preclinical • Oncology